Using the bully pulpit

first_imgJoseph B. Martin has kept a journal since 1978. Some of the resultant leather-bound books hold minutiae — from records of lunch meetings to calls, musings, and spontaneous ideas. But other logbooks, deeply private, were never shared, so when he decided to write a memoir, he turned to the volumes in which he’d documented his life.His book “Alfalfa to Ivy: Memoir of a Harvard Medical School Dean” “began as a family memoir,” said Martin, former dean of Harvard Medical School (HMS) and the Edward R. and Anne G. Lefler Professor of Neurobiology.“My family … emigrated from Switzerland to Pennsylvania to Canada, but my parents never took Canadian citizenship,” he said. “So I was born a dual citizen, which was very convenient to move back and forth across the border. I call myself an American with Canadian roots.”“But as I kept writing, I started to develop thoughts about academic leadership — leading by listening — and I realized there were some lessons I’d learned along the way that might be valuable.”Growing up in Duchess, Alberta, a remote Mennonite prairie town, gave Martin a humble, relatable quality that’s unmistakable in his professional life and writing. There are passages in his book about his boyhood dog, and a near-death experience involving a fall from a horse. And Martin peppers the book with family photographs of the idyllic countryside he roamed until going away to the University of Alberta at age 16.“My teachers could see I was bored, and skipped me,” he said. Martin knew he wanted to be a doctor from the get-go. “My earliest memory,” he recalled, “is walking across a field when I was 4 or 5 years old and thinking, ‘I want to be a doctor, I want to help people.’ And I wasn’t trying to escape my community, but I really had a passion, led, in part, by hearing the stories of the missionaries who came through our community from Africa, India, where they’d been working.”By his own admission, Martin was an awful university student. “That first year, I went home for Canadian Thanksgiving, and I didn’t want to go back. I was petrified. I flunked my first English paper, I flunked my first physics exam,” he said. “I thought it was all over. But by the end of the year, I was able to pick up and pass. I started medical school two years later, and by that time I was first in the class.”Martin’s career has taken him from McGill University to Massachusetts General Hospital (MGH) to the University of California, San Francisco (UCSF), where he served as chancellor. Harvard President Neil Rudenstine wooed Martin from UCSF to become dean of Harvard Medical School (HMS) in 1997, a job Martin made clear he never expected, nor necessarily wanted.“At MGH, I’d observed the dean’s role … I thought it was a terrible job. I said to my wife, ‘That’s a job I’ll never take.’ But as chancellor of UCSF, I missed the close relationships with students and faculty, and I was missing the fun of teaching,” he said.Martin’s deanship has been heralded for unifying a fragmented HMS, improving communication, encouraging collaboration, and diversifying departments, all while leading the School under three very different Harvard presidencies.“I’ve read many academic memoirs, and I didn’t want to write another one that pontificated about my accomplishments, but about the process of how you get things done,” said Martin. “Academic leadership is hard and erratic and complicated by the big egos that you work with, and some things go well and some things flunk. And I wanted this book to be a personal illustration of how those things arose, and were dealt with, and walked away from if they weren’t working.”Martin stepped down in 2007, after a decade-long tenure highlighted by Martin and his team successfully locating the gene for Huntington’s disease, an extraordinary moment for him.“One of my principles of leadership is that you do your best work within the first decade,” he said. “I’ve always felt that the leadership of the most effective sort is not ostentatious, it’s not using the bully pulpit to advertise who you are, but to use your position to try to make the community in which you work a better place.”last_img read more

Business as usual

first_imgThe Sinaloa Cartel, led by the recently captured Joaquín “El Chapo” Guzmán, is responsible for an estimated 25 to 50 percent of all illegal drugs that come into the United States through Mexico.According to experts, Guzmán’s organization has annual revenues of more than $6 billion, and is one of the main culprits behind the spiral of violence in Mexico that has claimed more than 100,000 lives.The Gazette spoke with Evelyn Krache Morris, an associate with the International Security Program at the Belfer Center for Science and International Affairs, about the effects of El Chapo’s arrest on the Mexican drug trade. Krache Morris is writing a book on the history of Mexican transnational criminal networks and their impact on U.S. relations with Mexico. GAZETTE: The number of people killed in Mexico due to drug-related violence is staggering. Between 2007 and 2014, there were around 164,000 deaths, more than the number of civilian deaths in the wars in Afghanistan and Iraq. And yet this tragedy doesn’t get a lot of attention here. Why is that?KRACHE MORRIS: I think it doesn’t get a lot of attention because it doesn’t fit into what we have grown to understand as threats to the United States. It’s seen as a Mexican problem that doesn’t affect the United States because it’s not seen as a terrorist threat. It’s not ISIS or al-Qaida. And because of that, the violence is largely ignored. To the extent it is discussed, it is often in terms of “drug dealers killing other drug dealers.” That is as sophisticated as the rhetoric has gotten.GAZETTE: What impact will El Chapo’s arrest have on the drug trade in Mexico?KRACHE MORRIS: As long as there is money to be made, and with such a profitable market next door, this business is not going to go away, because if it’s not El Chapo, it’s going to be someone else. There is too much money to be made.GAZETTE: How did he become the world’s most powerful drug trafficker?KRACHE MORRIS: Separate from the fact that he’s a murderous criminal, he’s a very good businessman. In order to create and run an organization the size and scope of Sinaloa, that’s really a requirement. Also, he was quite adept at playing off other transnational criminal networks against each other within Mexico. El Chapo was, at least, the symbolic head of what most people call the Sinaloa Cartel. I think “cartel” is the wrong term, because his organization is involved in drug trafficking, particularly heroin and meth, but also in a number of other businesses, including smuggling people and pirated software.Evelyn Krache Morris is an associate with the International Security Program at the Belfer Center for Science and International Affairs. Kris Snibbe/Harvard Staff PhotographerGAZETTE: What’s the term you use to describe these criminal organizations?KRACHE MORRIS: The term “drug trafficking organizations” gets closer, but drugs are only one of the products that these organizations are involved with. They’re also involved with things like avocado, limes, oil, and people. The term I like to use is transnational criminal networks, because that gets at the scope of what they’re doing.Cartel implies they’re working together to fix prices, like OPEC. That’s not how these organizations function at all. They’re extremely competitive. Much of the violence is the result of competition among these organizations for routes and transit points, particularly into the United States.GAZETTE: More than two decades ago, the drug trade was ruled by Colombian criminal organizations. How did the Mexican drug organizations take over?KRACHE MORRIS: The U.S. Coast Guard got much better at interdicting shipments coming through the Gulf of Mexico, and the Colombian organizations needed to find another way to get their products to the United States. They started working with Mexicans to get their products into Mexico, and then into the United States. As so often has happened, in various points with these organizations, the people working for you take over. That’s what happened. As the Colombian organizations were degraded, the Mexican organizations, which already had the logistics to get the products into the United States, took over.GAZETTE: Were there other factors behind the emergence of the Mexican drug organizations?KRACHE MORRIS: It was the dismantling of the Colombian drug organizations, but also the passage of NAFTA, which not only facilitated cross-border trade but also undermined Mexican agriculture. So you had lots of agricultural workers who were out of jobs and couldn’t support their families and were looking for something else to do. And one of the things they found was the drug trade.GAZETTE: How big a business is the drug trade? Many experts say their revenues amount to those of big global companies such as Nike ($30 billion) and Facebook ($18 billion).KRACHE MORRIS: The best number I found was $30 billion. It’s probably bigger than that now. It’s a multibillion-dollar industry spanning all across the globe. These Mexican transnational criminal networks are importing chemicals from China to make meth and fentanyl, or synthetic heroin, and they’re moving their products into the United States. They have connections in Europe, and they’re working with criminal organizations in Central America. They have a very broad reach.GAZETTE: What is the role of these drug organizations in the violence that is engulfing Mexico?KRACHE MORRIS: They have an enormous amount to do with the violence in Mexico. And one reason for the United States to dismiss this threat is to think that it’s drug dealers killing other drug dealers. That’s not true. It’s drug dealers killing police, journalists, and mayors.GAZETTE: Does the United States have any role in this wave of violence?KRACHE MORRIS: Mexico has stricter gun laws than the United States. About 75 percent of the guns used in Mexico are coming from the United States, where it is much easier to get them. States like Texas, where gun laws are quite liberal and share a border with Mexico, make it easy for guns to be trafficked into Mexico. The insatiable American demand for illegal drugs also, of course, contributes enormously to the violence and corruption in Mexico.GAZETTE: How have the Mexican criminal organizations evolved since they took over the Colombian organizations? What’s their role in the opiate epidemic in the United States?KRACHE MORRIS: Mexican organizations don’t sell much marijuana because it’s not profitable anymore. They’re into meth and heroin, which are extremely profitable.They’re filling a void that was created in part by cracking down on the so-called “pill mills,” by which people were getting prescription painkillers or opiates. They became harder to find, prices went up, and that didn’t mean that people were going to stop using them, but that they were going to find a substitute product. It was the classic business model of product substitution. The Mexican organizations filled that gap with heroin and fentanyl. Poppies can be grown in Mexico, but heroin has a high labor cost because the sap has to be harvested from the poppies and then it has to be refined. Fentanyl is less labor-intensive because it is made from chemicals that can be imported and thus it’s more profitable than heroin.GAZETTE: Speaking of profits, you’ve been advocating for more aggressive prosecution of the banks that have benefited themselves from laundering money from the drug trade. Could you tell us more about this?KRACHE MORRIS: A number of banks, including HSBC and Wachovia, have paid fines as result of investigations into money laundering. But these have been for trivial amounts. And calling it laundering is, in some cases, glorifying it. Bank branches in the capital of Sinaloa reconfigured their deposit windows into the shape of the boxes that men would bring, full of dollars, to shove them under the windows. Every bank has a compliance department to ensure they’re adhering to all the rules they need to. If you’re laundering money for Sinaloa, and if you have windows cut in your branches to make it easier for people to shove their dollars through, you’re not in compliance. If senior-level people at these big banks were subject to criminal prosecution, I think the banks would tighten things up.GAZETTE: What does it take to make a dent in the drug trade? Is it a combination of law enforcement, prosecution, interdiction, or maybe legalization?KRACHE MORRIS: The real pie in the sky, which is never going to happen, is uniform federal legalization of drugs like meth and heroin so there is no interstate price arbitrage and the laws are the same as well as the tax rates. This would dramatically cut down the profitability. That’s not going to happen. I think a solution that might happen is cracking down on the banks.GAZETTE: In your view, has the war on drugs been successful?KRACHE MORRIS: The long answer is I don’t think it’s being taken seriously enough. I think there’s still this attitude that says, “If you use drugs, you get what you deserve.” Filling the prisons with drug users so they can meet other drug users, or drug dealers, is not a great answer. Rehab takes a long time, it’s expensive, and it doesn’t work with sound bites. The short answer is that it has been a failure.last_img read more

A versatile vessel for next-gen therapeutics

first_img Research money supports scientific breakthroughs A dozen accelerator grants help cover biomedical development gap Related A protein called ARRDC1 (arrestin domain containing protein 1), closely related to a key protein identified in the asthma study, localizes “beautifully on the cell surface.” While ARRDC1 is not involved in airway response to beta-agonists or in asthma, Lu’s lab was stunned to discover that this protein drives the formation of small vesicles that transport materials in and out of the cell, essentially passing messages among neighboring cells in a way that was previously unrecognized. In the same 2012 PNAS publication, the research team noted that this mechanism explains how budding viruses like HIV and Ebola egress from within a cell host, coopting some components of ARMMs for their own purposes. The lab also showed, a few years later, that ARMMs can package and transfer bioactive receptor protein molecules between cells. Each ARMM vesicle is about one-millionth the volume of the cell, but it can hold hundreds of large molecules, and each cell can produce thousands of vesicles in a day.“Once we figured that out, we thought, well, if cells can transfer molecules from one cell to another through this mechanism, then you could actually replace the endogenous molecule with a therapeutic cargo,” said Lu.With funding and strategic advising from the Blavatnik Biomedical Accelerator, Lu proved the point. His lab demonstrated that its researchers could engineer ARMMs to deliver the tumor-suppressor protein p53 to cells that were lacking it, in mice. The research team published this work in Nature Communications in 2018, and generated important validating data on how the vesicles move within the body. Harvard OTD helped Lu develop a business plan and assemble a founding team, and in 2019, Vesigen received the Alexandria LaunchLabs Innovation Prize, a recognition of the startup’s “excellence in scientific innovation, leadership, and business strategy.”“The support from the Blavatnik Biomedical Accelerator was critical for my lab,” noted Lu. “It allowed me to complete most of the experiments described in our 2018 publication. Equally importantly, the Office of Technology Development and their Accelerator team helped me to make connections in industry and navigate the interactions with venture capitalists and pharmaceutical companies. They played a pivotal role in translating my lab’s innovations into the critical opportunities that led to the founding of Vesigen.”Lu is a cofounder of Vesigen and will serve on the company’s scientific advisory board while remaining full-time at Harvard Chan School to continue to focus primarily on his research and teaching.“My lab did not set out to find a therapeutic cure or a method to deliver therapeutics; we research biological questions that are relevant to public health,” he said. “But I’m very satisfied that some of the very basic findings in my lab have found these translation opportunities, and hopeful that our work may enable new therapies that save lives.”Entrepreneur Robert Millman will lead the company as cofounder and CEO. Millman previously founded and led two other companies to commercialize biomedical innovations from Harvard: Semma Therapeutics and CoStim Pharmaceuticals.“Many biotechs today, including some that I’ve worked with, have made it their mission to translate new biological tools, such as RNA interference, mRNA replacement, and DNA editing, into new therapies,” said Millman. “For most companies in this space, delivering the agent into the cell safely and efficiently is still an unsolved problem. With the ARMMs technology, we aim to overcome this barrier and expand the treatment options for patients.”Vesigen has named Morningside Ventures’ Gerald Chan, S.M. ’75, S.D. ’79, as chairman of the company, while Stephen Bruso of Morningside and Jürgen Eckhardt and Jak Knowles of Leaps by Bayer will join the board of directors. The advance could enable the development of new therapeutics for numerous conditions for which intracellular drug delivery is currently a roadblock. Vesigen intends to focus primarily on the targeted delivery of treatments for neurological diseases, oncology, and ophthalmology, while making engineered vesicles available to interested companies advancing treatments in other indications.Using his lab’s technology, Lu said, “If you want to deliver a therapeutic to the muscle, this vesicle can be engineered with specific surface molecules to target muscle cells.” In the case of eye diseases, he noted, “Injecting locally into the retina might avoid some of the unwanted immune responses and toxicity associated with viral delivery methods.”“ARMMs have the potential to solve some truly vexing problems for the biotech industry,” said Grant Zimmermann, managing director of business development in Harvard OTD. “For example, many therapeutic modalities would benefit from a drug-delivery mechanism with low immunogenicity, an intrinsic ability to traffic to specific tissues and cell types, and an efficient capability to deliver cargo directly to the cytoplasm of target cells. Additionally, RNA- or protein-based therapeutic cargo is directly loaded into the ARMM delivery vehicle during biogenesis, streamlining the biological manufacturing process. The innovations from the Lu Lab are extremely promising in these respects, and I’m thrilled to see them enter commercial development.”In Lu’s lab, the work began a decade ago. From a postdoc at Stanford, Lu was recruited to a faculty position at the Chan School to study the biology of the lung — specifically, how smooth-muscle tissue in the airway expands and contracts. Having expertise in genomic screening tools, Lu was able to sift through the genes active in these smooth-muscle cells and identify the signaling mechanism that regulates the cells’ receptivity to asthma drugs called beta-agonists. Lu subsequently expanded his work to examine more broadly the complex gene-environment interactions in asthma and in other multigenic human diseases such as diabetes and neurodegeneration. His work generated important insights, but along the way, he stumbled onto something else. With federal funds, Harvard helps drive local economy Harvard University’s Office of Technology Development (OTD) and the Harvard T.H. Chan School of Public Health today announced the launch of Vesigen Therapeutics, a startup company that aims to overcome the challenge of delivering next-generation therapeutics, such as gene-editing complexes, RNA molecules, and other large proteins, to intracellular targets in specific tissues of interest.Through an exclusive license agreement with Harvard, Vesigen will develop and commercialize novel drug-delivery technologies that originated in the lab of Quan Lu, professor of environmental genetics and physiology at the Harvard Chan School. In Lu’s lab, what began as a basic biological study of how cells communicate with each other ended up pointing, “completely unexpectedly,” to a new way of creating tiny, mobile capsules that efficiently direct therapeutic molecules to the cells where they’re needed. Support from Harvard’s Blavatnik Biomedical Accelerator enabled Lu’s research team at the Harvard Chan School to conduct validating studies and advance the nascent technology to a point of readiness for full commercial development.“We can harness the capability of these vesicles, called ARMMs” — for ARRDC1-mediated microvesicles — “to first package and then deliver therapeutic cargoes to the targeted tissues. That’s the ultimate goal of this, to enable next-generation therapeutics to reach their full potential in combating a wide range of diseases,” explained Lu.Vesigen launches with $28.5 million in Series A investment led by Leaps by Bayer and Morningside Ventures, with participation by Linden Lake Ventures and Alexandria Venture Investments. Vesigen will use the capital raised to build out the ARMMs platform as well as to advance numerous therapeutic agents into preclinical and clinical development.More than 80 percent of identified and biologically validated drug targets in humans are located inside cells. Yet some of the most promising new therapeutics, such as CRISPR/Cas9 genome editing complexes or mRNA or RNAi molecules, are large proteins and nucleic acids that cannot cross the cell membrane without help. Several approaches, including adeno-associated viruses and lipid nanoparticles, rely on a natural process called endocytosis to deliver their cargo into cells. The drawback is that most of what enters the cell in this way ends up channeled to the lysosomes and degraded, resulting in low efficiency. The key innovation from Lu’s lab stems from the discovery of a previously unrecognized mechanism in the cell membrane that allows it to accept deliveries without, essentially, sending them to be destroyed.Image courtesy of Vesigen Therapeutics “We can harness the capability of these vesicles, called ARMMs, to first package and then deliver therapeutic cargoes to the targeted tissues. That’s the ultimate goal of this, to enable next-generation therapeutics to reach their full potential in combating a wide range of diseases.” — Quan Lu, Harvard Chan School The Daily Gazette Sign up for daily emails to get the latest Harvard news. A bridge for promising researchlast_img read more

Wicked Hot Shot! Meet London’s Newest Elphaba, Emma Hatton

first_img View Comments Get a glimpse of Wicked’s new Elphaba before she meets the Wizard! After serving as the Elphaba standby at the Apollo Victoria Theatre, Emma Hatton will succeed Jennifer DiNoia in the role of the green witch beginning February 2. Hatton will star alongside Savannah Stevenson as Glinda. Check out this gorgeous shot of the new Elphie by Matt Crockett, then catch Wicked in the West End…and if you’ve already seen it, catch it again!last_img

Adam Chanler-Berat & More to Join Phillipa Soo in Amelie

first_img Related Shows Broadway alum Adam Chanler-Berat (Peter and the Starcatcher) and more will join the previously announced Tony nominee Phillipa Soo in the musical adaptation of Amélie. The tuner is scheduled to play a limited pre-Broadway engagement December 4 through January 16, 2017 at L.A.’s Ahmanson Theatre and is aiming to land on the Main Stem in the spring of 2017.The cast will also include Emily Afton, Alyse Alan Louis, David Andino, Randy Blair, Heath Calvert, Alison Cimmet, Savvy Crawford, Manoel Felciano, Harriett D. Foy, Maria-Christina Oliveras, Tony Sheldon, Jacob Keith Watson and Paul Whitty.Directed by Pam MacKinnon and based on the 2001 French film, Amélie features music by Daniel Messé, lyrics by Nathan Tysen and Messé, along with a book by Craig Lucas. The musical follows the journey of the inquisitive and shy Amélie (Soo) who turns the streets of Montmartre into a world of her own imagining, while secretly orchestrating moments of joy for those around her. After discovering a mysterious photo album and meeting a handsome stranger, Amélie realizes that helping others is easier than participating in a romantic story of her own.Samantha Barks previously led the world premiere of Amélie at the Berkeley Repertory Theatre opposite Chanler-Berat last year. Amelie View Commentscenter_img Adam Chanler-Berat & Phillipa Soo (Photo: Joan Marcus) Show Closed This production ended its run on May 21, 2017last_img read more

Plenty, Starring Rachel Weisz & Corey Stoll, Extends Again

first_img Plenty Related Shows Rachel Weisz & Corey Stoll in ‘Plenty'(Photo: Joan Marcus) View Commentscenter_img The first major New York revival of David Hare’s Plenty has extended once again off-Broadway. Directed by David Leveaux and headlined by Rachel Weisz and Corey Stoll, the show began previews on October 4 and will run through December 1, instead of November 20. Opening night has also been pushed back and is now scheduled for October 23 (from October 20) at the Public Theater.The company also includes Pun Bandhu, Ken Barnett, Emily Bergl, Dani De Waal, Mike Iveson, Byron Jennings, LeRoy McClain, Tim Nicolai, Paul Niebanck, Ann Sanders, Benjamin Thys and Liesel Allen Yeager.One of the most celebrated plays in the Public’s history, the groundbreaking play is the story of Susan Traherne (Weisz), a fiercely intelligent British secret agent flown into France during the Second World War. Susan’s experiences among her war-time colleagues and over the two decades that follow are distilled in powerful scenes in this endlessly layered work about a woman of remarkable bravery, who cannot find in peacetime the values and relationships she cherished in war. Show Closed This production ended its run on Dec. 1, 2016last_img read more

McWatters talks reg relief legislation, actions from NCUA

first_img continue reading » NCUA Acting Chair J. Mark McWatters discussed recommendations to “achieve real relief while maintaining safety and soundess” before the Senate Banking Committee Thursday, part of a hearing on regulators’ role in fostering economic growth. McWatters’ appearance before the committee was part of a series on fostering economic growth, a series CUNA testified for earlier this month.The committee asked NCUA to identify ways to ease regulatory burden through legislation. McWatters addressed several proposals.These include legislation that would:Provide NCUA with enhanced flexibility to write rules to address regulatory relief situations under the Federal Credit Union Act.Allow federal credit unions with a community or single-bond charter the opportunity to add underserved areas to a field of membership. 14SHARESShareShareSharePrintMailGooglePinterestDiggRedditStumbleuponDeliciousBufferTumblrlast_img read more

Binghamton Jewish organizations struggle to adjust to new threats

first_imgAccording to data from the Anti-Defamation League’s Center on Extremism there were nearly two thousand anti-semitic incidents reported in the United States in 2018. This leaves congregation leaders with a dilemma. The recent uptick in anti-semitism has officials wondering if armed security is needed at the Temple and if so how much. Coker says this presents its own challenges. “It would be a multifaceted approach and we would also lean on other agencies and their resources,” she said. Captain Kate Newcomb of the Broome County Sheriff’s Office says the department is prepared to step in if such a threat is ever made in Broome County. “I think the last couple of years anti-semitic threats have been a challenge to Jewish organizations of all kinds,” said Rachel Coker, President of Temple Concord in Binghamton. Coker says she hopes that there will come a time when security is no longer a concern for her congregants. “There are people who are here looking for a place of meditation and peace and it’s hard to reconcile that for some people with the presence of someone who’s holding a gun,” she said. BINGHAMTON (WBNG) — In the wake of bomb threats made against 18 Jewish Community Centers across New York State, one local temple leader is speaking out about a recent rise in anti-semitism. “We want people to come here we want people to study and pray with us but at the same time we need to keep the people who are already inside safe,” said Coker. last_img read more

Robin van Persie names his Ballon d’Or top three with no place for Lionel Messi or Cristiano Ronaldo

first_imgVan Persie named his Ballon d’Or top three (Picture: Soccrates/Getty Images)Robin van Persie named the three players he believes deserves to be on the podium for the Ballon d’Or, and snubbed both Lionel Messi and Cristiano Ronaldo. The former Arsenal and Manchester United striker believes Bayern Munich’s Robert Lewandowski should win football’s most coveted individual prize. Premier League duo Kevin De Bruyne and Sadio Mane, of Manchester City and Liverpool respectively, are the other players to make his top three. Should Van Persie’s list come to fruition, it would be the first time since 2006 that neither Messi nor Ronaldo finished in the top three.ADVERTISEMENTSince 2007 only Luka Modric (2018) has won the award ahead of the duo, while Lewandowski, De Bruyne and Mane have never finished inside the top three. Robin van Persie names his Ballon d’Or top three with no place for Lionel Messi or Cristiano Ronaldo Advertisement Metro Sport ReporterThursday 9 Jul 2020 7:40 amShare this article via facebookShare this article via twitterShare this article via messengerShare this with Share this article via emailShare this article via flipboardCopy link2.2kShares Commentcenter_img Advertisement Lewandowski has been in great form (Picture: AFP via Getty)Prollific Poland striker Lewandowski scored 52 goals in 43 appearances in all competitions last season, helping his side to win the Bundesliga and the DFB-Pokal while they are still in contention for the Champions League next month.AdvertisementAdvertisementHe is the top scorer in European competition, having scored 11 times in six Champions League matches, and no one in Europe’s top-five leagues has matched his 34-goal tally. More: FootballRio Ferdinand urges Ole Gunnar Solskjaer to drop Manchester United starChelsea defender Fikayo Tomori reveals why he made U-turn over transfer deadline day moveMikel Arteta rates Thomas Partey’s chances of making his Arsenal debut vs Man CityDe Bruyne has scored 11 times and provided 18 assists in the Premier League this season His side, Manchester City, have won the League Cup, are in the semi-finals of the FA Cup and still in contention for the Champions League.Mane helped end Liverpool’s 30-year title drought by scoring 16 times and providing seven assists while he won the Club World Cup, but Jurgen Klopp’s men are not in contention for any more trophies this season, having failed to defend the Champions League and losing in both domestic cup competitions. Mane and De Bruyne make up Van Persie’s top three (Picture: Getty)Messi could end up trophyless, with Barcelona trailing Real Madrid in La Liga, although he will hope to inspire his side to Champions League victory. He has netted 22 goals and provided 19 assists in La Liga alone this season. Ronaldo, meanwhile, will likely win Serie A with Juventus, having scored more goals for the club in a single season than any player in 60 years. He has banged in 26 goals in 27 Serie A matches and the Italian giants remain in contention to win the Champions League. Whoever wins Europe’s top club prize could take a massive step forwards to winning the Ballon d’Or, but Van Persie thinks Lewandowski is the man who should get his hands on the trophy.Should Robert Lewandowski win the Ballon d’Or?Yes0%No0%Share your resultsShare your resultsTweet your resultsMORE: Liverpool manager Jurgen Klopp explains why he benched Sadio Mane and Andy Robertson for Brighton clashMORE: Cesc Fabregas names Liverpool legend Steven Gerrard as the best opposition player he’s ever facedFollow Metro Sport across our social channels, on Facebook, Twitter and Instagram.For more stories like this, check our sport page.last_img read more

Orianna name got first two residents on board

first_imgOrianna Lifestyle Resort at Sandstone PointA CRUISE on the P&O Oriana in 1975 has led a couple to buy into Orianna Lifestyle Resort at Sandstone Point.Roly and Glenis Ong, the first residents of Orianna Lifestyle Resort, decided to buy into the community when they saw the resort’s name.“The Oriana was the first cruise we ever went on and we thought it must be a sign when we saw the advertisement,” Mr Ong said.“We always said we would retire at Bribie Island, and we love being by the water, so the position of Orianna … was absolutely ideal.”More from newsLand grab sees 12 Sandstone Lakes homesites sell in a week21 Jun 2020Tropical haven walking distance from the surf9 Oct 2019Orianna Lifestyle Resort is a new over-50s community with 122 homes, resort-style facilities and a communal boat.Orianna Lifestyle Resorts general manager Brett Robinson said it was exciting to welcome the first residents and see the community come to life.He said the slab for Orianna’s Recreation Centre had been poured, with construction now well under way.“The Recreation Centre will be the hub for the community to catch up, have a drink at the bar, grab a coffee with friends, or strike up a game of billiards,” Mr Robinson said.“It will also feature twin bowling greens, a resort-style pool, private gym, cinema and a workshop.”Mr Robinson said by designing the strictly owner-occupier resort with a high level of amenity, Orianna would provide a genuine sense of belonging and community.The resort has two and three-bedroom homes for the over 50s, starting from $375,000. Some have double lockup garages.last_img read more